BLOOMFIELD HILLS, Mich., December 20, 2024--(BUSINESS WIRE)--Zivo Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, reports favorable results from a study conducted in collaboration with the University of Delaware that evaluated the potential of ZIVO’s proprietary active ingredients to reduce the transmission of Low Pathogenicity Avian Influenza (LPAI) virus among poultry.
Key findings of statistical significance from the study include:
A reduction in viral titers (viral shedding) in infected birds receiving ZIVO’s products compared with untreated infected controls.
A delay in transmission of LPAI when healthy birds were exposed to infected birds, suggesting a slower and less aggressive spread of disease.
The two-part controlled study evaluated the efficacy of ZIVO’s proprietary active ingredients, previously shown to be efficacious for mitigating the effects of coccidiosis in broiler chickens, against LPAI.
In the first part of the study, infected birds receiving a mixture of ZIVO’s proprietary active ingredients showed an early significant decrease in viral titers compared with untreated, infected controls, thereby reducing amount of detectable virus that was shed. At the end of the study, although not significant in nature, a numerical decrease in virus was noted in birds receiving ZIVO’s product. In the second part, healthy chickens were housed with infected birds, replicating a real-world, high-risk environment for disease transmission. Compared to an untreated control group, birds that received ZIVO’s proprietary active ingredients that were housed with infected birds experienced a statistically significant delay in viral detection. This observed delay suggests that ZIVO’s products limit viral replication within a host.
These favorable results indicate that ZIVO’s proprietary active ingredients represent potential preventative measures for reducing the spread of LPAIV in commercial poultry operations and enhancing overall flock health.
Multiple products were explored to identify the most effective strategies against LPAI. While some products were better at lowering the viral titer, others were more effective at slowing the spread, suggesting that an optimal product configuration could provide more comprehensive protection. The study’s positive outcomes justify further research and product development, supporting the potential of ZIVO’s pipeline to address both LPAIV infections as well as a broad spectrum of other viral challenges faced by the poultry industry.
"We are highly encouraged by the outcomes of this study," said John B. Payne, Chairman and CEO of ZIVO Bioscience. "The University of Delaware’s findings provide compelling evidence that our feed ingredients could be valuable tools in mitigating the risk of avian influenza outbreaks without the limitations associated with vaccines. Reducing disease transmission can positively impact both animal welfare and the operations of producers. These study results represent a significant milestone in our efforts to deliver science-driven, sustainable solutions to address serious challenges facing the global poultry industry."
"This study sponsored by ZIVO Bioscience enabled us to evaluate novel interventions to provide immune support for poultry," said Brian Ladman, Ph.D., Principal Investigator at the University of Delaware’s Department of Animal and Food Sciences. "The findings demonstrate that further investigation into ZIVO’s active ingredients to safeguard poultry flocks against viral outbreaks is warranted. I look forward to continuing to work with ZIVO to identify novel solutions to this critical public health issue."
"With these preliminary efficacy results, we are now planning additional studies to further evaluate the benefits of our products. We are at a critical point in our mission to find a viable treatment for avian influenza, and the need for an effective therapy grows every day," said John Payne. "We will continue towards commercialization of our coccidiosis treatment while utilizing these preliminary results to further our partnership dialogues. I am confident that ZIVO can take the next step toward evaluating this potential breakthrough technology."
About ZIVO Bioscience
Zivo Bioscience, Inc. is a research and development company with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent pending inventions for applications in human and animal health. Please visit www.zivobioscience.com for more information.
Forward Looking Statements
Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including with respect to the Company’s product candidate’s potential to generate revenues and the expected time frame for results of future studies. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. Although ZIVO believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that our strategic partnerships may not facilitate the commercialization or market acceptance of our products; risks that we will be unable to increase production sufficient to meet our expected demand; risks that our products may not be ready for commercialization in a timely manner or at all; risks that our products will not perform as expected based on results of our pre-clinical and clinical trials; our ability to raise additional funds; uncertainties inherent in the development process of our products; changes in regulatory requirements or decisions of regulatory authorities; the size and growth potential of the markets for our products; the results of clinical trials, our ability to protect our intellectual property rights and other risks, uncertainties and assumptions, including those described under the heading "Risk Factors" in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and ZIVO undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.
